This article was originally published in The Gray Sheet
Sign definitive merger agreement under which all outstanding shares of dental supply firm Dentsply will be exchanged for 14.4 mil. shares of dental equipment manufacturer Gendex' common stock. Under the preliminary merger agreement, Dentsply stockholders were to receive 13.8 mil. shares of Gendex stock ("The Gray Sheet" Jan. 25, p. 23).
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.